ROOT Brands Launches CRUSH and SCULPT to Address GLP-1 Medication Aftermath
Event summary
- ROOT Brands introduced CRUSH and SCULPT on April 8, 2026, targeting metabolic and muscle support for GLP-1 medication users.
- CRUSH focuses on metabolic function and cellular energy, while SCULPT supports lean muscle and body composition.
- The products address the 'GLP-1 gap'—challenges like weight regain and muscle loss post-medication use.
- ROOT Brands positions these as non-pharmaceutical alternatives for long-term wellness support.
The big picture
ROOT Brands is capitalizing on the growing awareness of post-GLP-1 medication challenges, a gap left by drugs like Ozempic and Wegovy. The launch of CRUSH and SCULPT reflects a broader trend of wellness companies developing science-driven alternatives to pharmaceutical dependency. The strategic move positions ROOT Brands as a key player in the evolving weight management and metabolic health market.
What we're watching
- Market Adoption
- Whether CRUSH and SCULPT can capture significant market share among GLP-1 medication users.
- Regulatory Scrutiny
- The pace at which regulatory bodies review claims about metabolic and muscle support.
- Competitive Response
- How traditional pharmaceutical companies react to ROOT Brands' non-pharmaceutical approach.
Related topics